Q151M-Mediated Multinucleoside Resistance: Prevalence, Risk Factors, and Response to Salvage Therapy

Mauro Zaccarelli, Carlo Federico Perno, Federica Forbici, Fabio Soldani, Sandro Bonfigli, Caterina Gori, Maria Paola Trotta, Maria Concetta Bellocchi, Giuseppina Liuzzi, Roberta D'Arrigo, Patrizio De Longis, Evangelo Boumis, Rita Bellagamba, Valerio Tozzi, Pasquale Narciso, Andrea Antinori

Research output: Contribution to journalArticlepeer-review


Among 470 patients with acquired immune deficiency syndrome and/or human immunodeficiency virus infection (HIV/AIDS) who underwent genotype resistance testing (GRT) after the failure of therapy, 17 (3.6%) harbored the Q151M mutation. The Q151M mutation was associated with younger age, lower CD4 + lymphocyte count, higher HIV RNA level, and treatment with >2 pre-GRT regimens. By contrast, the Q151M mutation was inversely associated with lamivudine administration. A full reversion of the Q151M mutation was observed in 5 of 5 patients who underwent treatment interruption after GRT. The reversion was followed by a response to salvage therapy in 4 (80%) of 5 patients.

Original languageEnglish
Pages (from-to)433-437
Number of pages5
JournalClinical Infectious Diseases
Issue number3
Publication statusPublished - Feb 1 2004

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Q151M-Mediated Multinucleoside Resistance: Prevalence, Risk Factors, and Response to Salvage Therapy'. Together they form a unique fingerprint.

Cite this